- Home
- PESI vs TLSI Comparison
PESI vs TLSI Comparison
Compare PESI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PESI
- TLSI
- Stock Information
- Founded
- PESI 1990
- TLSI 2010
- Country
- PESI United States
- TLSI United States
- Employees
- PESI N/A
- TLSI N/A
- Industry
- PESI Environmental Services
- TLSI Medical Specialities
- Sector
- PESI Industrials
- TLSI Health Care
- Exchange
- PESI Nasdaq
- TLSI Nasdaq
- Market Cap
- PESI 191.9M
- TLSI 124.9M
- IPO Year
- PESI 1992
- TLSI N/A
- Fundamental
- Price
- PESI $10.68
- TLSI $4.69
- Analyst Decision
- PESI Strong Buy
- TLSI Strong Buy
- Analyst Count
- PESI 1
- TLSI 6
- Target Price
- PESI $18.00
- TLSI $11.75
- AVG Volume (30 Days)
- PESI 139.0K
- TLSI 36.4K
- Earning Date
- PESI 03-12-2025
- TLSI 11-14-2024
- Dividend Yield
- PESI N/A
- TLSI N/A
- EPS Growth
- PESI N/A
- TLSI N/A
- EPS
- PESI N/A
- TLSI N/A
- Revenue
- PESI $67,134,000.00
- TLSI $26,891,000.00
- Revenue This Year
- PESI N/A
- TLSI $60.96
- Revenue Next Year
- PESI $52.66
- TLSI $53.65
- P/E Ratio
- PESI N/A
- TLSI N/A
- Revenue Growth
- PESI N/A
- TLSI 67.90
- 52 Week Low
- PESI $7.63
- TLSI $3.50
- 52 Week High
- PESI $16.25
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- PESI 40.98
- TLSI 51.68
- Support Level
- PESI $10.10
- TLSI $4.72
- Resistance Level
- PESI $10.79
- TLSI $5.32
- Average True Range (ATR)
- PESI 0.51
- TLSI 0.31
- MACD
- PESI 0.07
- TLSI 0.01
- Stochastic Oscillator
- PESI 46.03
- TLSI 47.52
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: Treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.